GlobeNewswire

PCI Biotech: Preclinical research collaboration with big pharma ended

Share

Oslo (Norway), 21 October 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today informed that AstraZeneca has elected not to enter into a definitive agreement for the fimaNAc technology.

Encouraging preclinical results have continued to be achieved with the fimaNAc platform in this collaboration and the decision not to enter into a definitive agreement is primarily based on a strategic evaluation of current development needs. The companies plan to work together to publish the preclinical results from this collaboration.

Per Walday, CEO of PCI Biotech, comments: “This is of course disappointing news, but the collaboration has provided PCI Biotech with valuable scientific knowhow from working with a big biopharma company over the last 5 years. We will utilise this important knowhow, together with the generated preclinical results, for the further development of the fimaNAc asset. We see great potential for further development of our intracellular delivery technology, not least within the emerging field of mRNA.”

The preclinical research collaboration was initiated in September 2015 to determine whether PCI Biotech’s fimaNAc technology had the potential to enhance the delivery of the collaborator’s nucleic acid therapeutic compounds. The experimental collaboration ended in December 2019, with an additional 12 months evaluation period until the end of 2020 to determine the potential for a further collaboration.

Contact information:    
Per Walday, CEO            
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech         
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements    
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

RomReal: Third Quarter (Q3) 2020 Results and Investor Presentation26.11.2020 23:00:00 CETPress release

RomReal hereby announces the results of the third quarter of 2020 via the report and investor presentation attached to this message. A webcast presentation will also be uploaded on our website www.romreal.com by 9am CET tomorrow 27 November 2020. For further information please contact: Harris Palaondas Investor Relations RomReal investors@romreal.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments RomReal - Q3 2020 PresentationRomReal - Q3 2020 Report

PRESS RELEASE: NACON: GREEDFALL EXTEND ITS JOURNEY WITH A NEW EXPANSION AND A RELEASE ON PLAYSTATION 5 AND XBOX SERIES S/X26.11.2020 18:00:00 CETPress release

GREEDFALL EXTEND ITS JOURNEY WITH A NEW EXPANSION AND A RELEASE ON PLAYSTATION 5 AND XBOX SERIES S/X Lesquin (France), November 26, 2020 – Following the success of GreedFall, which sold more than a million copies in less than a year, and considering the enthusiasm of all those who travelled the rich lands of Teer Fradee, NACON and Focus Home Interactive are happy to announce a new partnership aiming to expand the game with new content, as well as a release on PlayStation 5 and Xbox Series S/X. The two companies have thus reached an agreement, in which Focus Home Interactive will be in charge of the publishing of the upcoming additional content and expansion, as well as the PlayStation 5 and Xbox Series S/X versions of GreedFall. The GreedFall brand is now integrated as part of the NACON portfolio. Released September 10, 2019, GreedFall is an RPG experience in which you explore uncharted lands seeping with magic, filled with secrets and fantastic creatures. With diplomacy, deception and

KBC Group: KBC finalises acquisition of OTP Banka Slovensko (Slovakia)26.11.2020 18:00:00 CETPress release

Joint Press Release Outside trading hours – Regulated information* Brussels, Budapest, Bratislava – 26 November 2020 – 6 p.m. CET KBC finalises acquisition of OTP Banka Slovensko (Slovakia) Belgium’s KBC Group and OTP Bank, the Hungarian parent company of OTP Banka Slovensko (Slovakia), today closed the agreement announced on 17 February 2020 for KBC Bank NV to acquire ownership of 99.44% of the shares in OTP Banka Slovensko, a.s. (OTP Banka Slovensko). The remaining shares are held by a number of private individuals. The transaction received regulatory approval from the National Bank of Slovakia (NBS), the National Bank of Belgium (NBB), the European Central Bank (ECB) and the Antimonopoly Office of the Slovak Republic. It has only a limited impact (-0.2%) on KBC’s solid capital position, keeping KBC’s excellent 3Q2020 CET1 ratio of 16.6% (Basel III fully loaded, Danish compromise) well above regulatory minimum capital requirements. As a result of the transaction, KBC Bank NV is now t

IMCD to acquire the personal care business of Turkish distributor Ejder Kimya26.11.2020 17:45:00 CETPress release

ROTTERDAM, The Netherlands (26 November 2020) – IMCD N.V. (“IMCD”), a leading distributor of speciality chemicals and ingredients, today announces that it has successfully signed an agreement to acquire the personal care business of Ejder Kimya İlaç Danışmanlık Sanayi ve Ticaret A.Ş. (“Ejder Kimya”). Ejder Kimya was founded in 1999 and is a Turkish chemicals distributor of raw materials for personal care and pharmaceuticals products and food additives. It has a strong and solid position in the personal care market in Turkey. Ejder Kimya’s personal care business generated a revenue of € 4.7 million in 2019. Aylin Zakuto, Managing Director IMCD Turkey, comments: “This acquisition is a solid step to strengthen IMCD Turkey’s footprint in the personal care market in line with IMCD’s global growth strategy. Adding Ejder Kimya’s personal care market expertise and extensive portfolio to IMCD will expand our offered solutions to customers and accelerate the growth of our suppliers in the person

Information regarding the early redemption of the 2021 bonds26.11.2020 17:00:00 CETPress release

Press release: Information to Bondholders 26 November 2020 Information regarding the early redemption of the 2021 bonds NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS PRESS RELEASE. THE DISTRIBUTION OF THIS PRESS RELEASE IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND THE UNITED KINGDOM) MAY BE RESTRICTED BY LAW. On 29 October 2020, Cembrit Group A/S exercised its right to make a voluntary early redemption of its outstanding senior secured callable bonds maturing on 20 March 2021 with ISIN SE0009722887 and outstanding amount of EUR 115

Saniona AB’s Nomination Committee for the Annual General Meeting 202126.11.2020 16:00:00 CETPress release

PRESS RELEASE November 26, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the composition of the Nomination Committee for the Annual General Meeting 2021. Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall be comprised of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2020, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and New Leaf Venture Partners. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB’s Nomination Committee. The Nomination Committee’s members are: Søren Skjærbæk, Partner at Ursus law firm, Vejle, Denmark, appointed by Jørgen DrejerJohn Haurum